{
    "root": "63941bc7-6690-4f7d-9672-93d0b459990b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Celecoxib"
    },
    "value": "20241231",
    "ingredients": [
        {
            "name": "CELECOXIB",
            "code": "JCX84Q7J1L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "celecoxib indicated",
    "contraindications": "• lowest effective shortest duration consistent individual patient treatment goals . ( 2.1 ) • oa : 200 mg daily 100 mg twice daily . ( 2.2 , 14.1 ) • rheumatoid arthritis : 100 mg 200 mg twice daily . ( 2.3 , 14.2 ) • jra : 50 mg twice daily patients 10 kg 25 kg . 100 mg twice daily patients 25 kg . ( 2.4 , 14.3 ) • : 200 mg daily single dose 100 mg twice daily . effect observed 6 weeks , trial 400 mg ( single divided doses ) may benefit . ( 2.5 , 14.4 ) • ap pd : 400 mg initially , followed 200 mg dose needed first day . subsequent days , 200 mg twice daily needed . ( 2.6 , 14.5 ) hepatic impairment : reduce daily dose 50 % patients moderate hepatic impairment ( child-pugh class b ) . ( 2.7 , 8.6 , 12.3 ) poor metabolizers cyp2c9 substrates : consider dose reduction 50 % ( alternative management jra ) patients known suspected cyp2c9 poor metabolizers . ( 2.7 , 8.8 , 12.3 )",
    "warningsAndPrecautions": "celecoxib capsules 50 mg opaque white/opaque white hard gelatin capsules size “ 5 ” imprinting “ 134 ” body red ink “ ” cap red ink filled white off-white colored granular powder . ndc 62332-140-30 bottle 30 capsules child-resistant closure ndc 62332-140-60 bottle 60 capsules child-resistant closure ndc 62332-140-91 bottle 1000 capsules ndc 62332-140-08 carton 80 ( 10 x 8 ) unit-dose capsules celecoxib capsules 100 mg opaque white/opaque white hard gelatin capsules size “ 3 ” imprinting “ 135 ” body blue ink “ ” cap blue ink filled white off-white colored granular powder . ndc 62332-141-30 bottle 30 capsules child-resistant closure ndc 62332-141-60 bottle 60 capsules child-resistant closure ndc 62332-141-31 bottle 100 capsules child-resistant closure ndc 62332-141-71 bottle 500 capsules ndc 62332-141-91 bottle 1000 capsules ndc 62332-141-08 carton 80 ( 10 x 8 ) unit-dose capsules celecoxib capsules 200 mg opaque white/opaque white hard gelatin capsules size “ 1 ” imprinting “ 136 ” body golden yellow ink “ ” cap golden yellow ink filled white off-white colored granular powder . ndc 62332-142-30 bottle 30 capsules child-resistant closure ndc 62332-142-60 bottle 60 capsules child-resistant closure ndc 62332-142-31 bottle 100 capsules child-resistant closure ndc 62332-142-71 bottle 500 capsules ndc 62332-142-91 bottle 1000 capsules ndc 62332-142-08 carton 80 ( 10 x 8 ) unit-dose capsules celecoxib capsules 400 mg opaque white/opaque white hard gelatin capsules size “ 00 ” imprinting “ 137 ” body green ink “ ” cap green ink filled white off-white colored granular powder . ndc 62332-143-30 bottle 30 capsules child-resistant closure ndc 62332-143-60 bottle 60 capsules child-resistant closure ndc 62332-143-71 bottle 500 capsules ndc 62332-143-10 carton 100 ( 10 x 10 ) unit-dose capsules storage : store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "celecoxib contraindicated following patients : • known hypersensitivity ( e.g . , anaphylactic serious skin ) celecoxib , components product [ ( 5.7 , 5.9 ) ] . • history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids , reported patients [ ( 5.7 , 5.8 ) ] . • setting cabg surgery [ ( 5.1 ) ] . • patients demonstrated allergic-type sulfonamides [ ( 5.7 ) ] .",
    "indications_original": "Celecoxib is indicated",
    "contraindications_original": "•  Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. ( 2.1 ) •  OA: 200 mg once daily or 100 mg twice daily. ( 2.2 , 14.1 ) •  RA: 100 mg to 200 mg twice daily. ( 2.3 , 14.2 ) •  JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg. ( 2.4 , 14.3 ) •  AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit. ( 2.5 , 14.4 ) •  AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed. ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.7 , 8.6 , 12.3 ) Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers. ( 2.7 , 8.8 , 12.3 )",
    "warningsAndPrecautions_original": "Celecoxib capsules 50 mg are opaque white/opaque white hard gelatin capsules size “5” having imprinting “134” on body with red ink and “A” on cap with red ink filled with white to off-white colored granular powder.  \n                  \n                  NDC 62332-140-30    bottle of 30 capsules with child-resistant closure\n                  NDC 62332-140-60    bottle of 60 capsules with child-resistant closure\n                  NDC 62332-140-91    bottle of 1000 capsules \n                  NDC 62332-140-08    carton of 80 (10 x 8) unit-dose capsules  \n                  \n                  Celecoxib capsules 100 mg are opaque white/opaque white hard gelatin capsules size “3” having imprinting “135” on body with blue ink and “A” on cap with blue ink filled with white to off-white colored granular powder.\n                  \n                  NDC 62332-141-30    bottle of 30 capsules with child-resistant closure\n                  NDC 62332-141-60    bottle of 60 capsules with child-resistant closure\n                  NDC 62332-141-31    bottle of 100 capsules with child-resistant closure\n                  NDC 62332-141-71    bottle of 500 capsules \n                  NDC 62332-141-91    bottle of 1000 capsules \n                  NDC 62332-141-08    carton of 80 (10 x 8) unit-dose capsules  \n                  \n                  Celecoxib capsules 200 mg are opaque white/opaque white hard gelatin capsules size “1” having imprinting “136” on body with golden yellow ink and “A” on cap with golden yellow ink filled with white to off-white colored granular powder. \n                  \n                  NDC 62332-142-30    bottle of 30 capsules with child-resistant closure\n                  NDC 62332-142-60    bottle of 60 capsules with child-resistant closure\n                  NDC 62332-142-31    bottle of 100 capsules with child-resistant closure\n                  NDC 62332-142-71    bottle of 500 capsules \n                  NDC 62332-142-91    bottle of 1000 capsules \n                  NDC 62332-142-08    carton of 80 (10 x 8) unit-dose capsules  \n                  \n                  Celecoxib capsules 400 mg are opaque white/opaque white hard gelatin capsules size “00” having imprinting “137” on body with green ink and “A” on cap with green ink filled with white to off-white colored granular powder.\n                  \n                  NDC 62332-143-30    bottle of 30 capsules with child-resistant closure\n                  NDC 62332-143-60    bottle of 60 capsules with child-resistant closure\n                  NDC 62332-143-71    bottle of 500 capsules \n                  NDC 62332-143-10    carton of 100 (10 x 10) unit-dose capsules\n                  \n                  \n                     \n                        Storage: \n                     Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Celecoxib is contraindicated in the following patients:  • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see Warnings and Precautions (5.7, 5.9)]. • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs, have been reported in such patients [see Warnings and Precautions (5.7, 5.8)].  • In the setting of CABG surgery [see Warnings and Precautions (5.1)]. • In patients who have demonstrated allergic-type reactions to sulfonamides [see Warnings and Precautions (5.7)]."
}